NDA 210331 · Alimera Sciences INC
Yutiq
Fluocinolone Acetonide · Intravitreal · Corticosteroid
DiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 12, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Oct 12, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
63
20 Phase 3, 7 recruiting
FAERS reports
2,444
757 serious, 42 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 19, 2026.
1. INDICATIONS AND USAGE YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ contains a corticosteroid and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. ( 1 )
Mechanism: Corticosteroids inhibit inflammatory responses to a variety of inciting agents including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Corticosteroids are thought to act by inhibition of phospholipase A 2 via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- YUTIQ · FLUOCINOLONE ACETONIDE 0.18MG · IMPLANT, INTRAVITREAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluocinolone Acetonide" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03568318 · 1,533 participants · Start Aug 9, 2018 · Primary completion Feb 16, 2021
Drug: Placebo; Upadacitinib and 1 more · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 193 sites in all
- Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular EdemaPivotal-lookingCompleted
Alimera SciencesIndustry
NCT00344968 · 956 participants · Start Sep 2007 · Primary completion Dec 2009
Drug: fluocinolone acetonide; Fluocinolone Acetonide · For: Diabetic Macular Edema
Sites: Atlanta, Georgia
- Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02260986 · 740 participants · Start Sep 2014 · Primary completion Aug 2015
Drug: Dupilumab; Placebo (for Dupilumab) · For: Atopic Dermatitis
Sites: Phoenix, Arizona; Hot Springs, Arkansas; Little Rock, Arkansas · 148 sites in all
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation RetinopathyPivotal-lookingRecruiting
Jaeb Center for Health ResearchAcademic, hospital or other
NCT05844982 · 600 participants (planned) · Start Nov 21, 2023 · Primary completion Dec 26, 2029
Drug: Faricimab; fluocinolone acetonide · For: Radiation Retinopathy; Visual Impairment
Sites: Palo Alto, California; Manchester, Connecticut; Tampa, Florida · 29 sites in all
- Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Otic Solution in the Treatment of Acute Otitis ExternaPivotal-lookingCompleted
Lee's Pharmaceutical LimitedIndustry
NCT04636957 · 600 participants · Start Jan 4, 2021 · Primary completion Oct 17, 2021
Drug: Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution; Ciprofloxacin 0.3% solution · For: Acute Otitis Externa
Sites: Shanghai, China
- Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03345914 · 367 participants · Start Nov 17, 2017 · Primary completion Jun 20, 2019
Drug: Dupilumab; Matching Placebo · For: Dermatitis, Atopic
Sites: Birmingham, Alabama; Gilbert, Arizona; Bakersfield, California · 61 sites in all
- A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)Pivotal-lookingActive, not recruiting
Alimera SciencesIndustry
NCT04469595 · 300 participants (planned) · Start Aug 31, 2020 · Primary completion Dec 31, 2024
Drug: Iluvien 0.19 MG Drug Implant; Aflibercept · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 40 sites in all
- Safety and Efficacy of Fluocinolone Acetonide Intravitreal ImplantsPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00407082 · 278 participants · Start Dec 2000 · Primary completion Sep 2005
Drug: fluocinolone acetonide intravitreal implant; Fluocinolone acetonide 2.1mg · For: Noninfectious Posterior Uveitis
Sites: Durham, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use519
- product dose omission issue199
- drug ineffective187
- pruritus166
- rash143
- no adverse event130
- diarrhoea115
- psoriasis95
- headache90
- fatigue89
- pain85
- nausea81
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 14 |
| 2006 | 7 |
| 2007 | 11 |
| 2008 | 9 |
| 2009 | 15 |
| 2010 | 17 |
| 2011 | 28 |
| 2012 | 32 |
| 2013 | 17 |
| 2014 | 26 |
| 2015 | 53 |
| 2016 | 75 |
| 2017 | 66 |
| 2018 | 73 |
| 2019 | 115 |
| 2020 | 163 |
| 2021 | 174 |
| 2022 | 286 |
| 2023 | 190 |
| 2024 | 585 |
| 2025 | 295 |
| 2026 | 185 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Yutiq (Fluocinolone Acetonide) · HCPCS J7314
2024 spending
$13.7M
Beneficiaries
1,218
1,386 claims
Per beneficiary
$11,238
2024 ASP limit $527.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,541,901 |
| 2021 | $6,285,301 |
| 2022 | $9,370,225 |
| 2023 | $11,403,309 |
| 2024 | $13,688,154 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interventions for melasma.
Rajaratnam R, Halpern J, Salim A, et al. · Cochrane Database Syst Rev 2010 · Systematic Review
- CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.
Chakravarthy U, Yang Y, Lotery A, et al. · Retina 2018 · Multicenter Study, Randomized Controlled Trial
- Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma.
Basit A, Rahman A, Uddin R · J Ayub Med Coll Abbottabad 2021 · Randomized Controlled Trial
- Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience.
Fallico M, Maugeri A, Lotery A, et al. · Sci Rep 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Are generic formulations equivalent to trade name topical glucocorticoids?
Stoughton RB · Arch Dermatol 1987 · Clinical Trial, Comparative Study
- Betamethasone dipropionate cream for the treatment of psoriasis. A collaborative evaluation.
Charney P · Arch Dermatol 1976 · Clinical Trial, Comparative Study
Sponsor: Alimera Sciences INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.